Eupraxia Pharmaceuticals (EPRX) Non Operating Income (2025 - 2026)

Eupraxia Pharmaceuticals' (EPRX) quarterly Non Operating Income came in at $3.3 million in Q1 2026, up 821.81% year-on-year from $359739.0 in Q1 2025, and up 821.81% on a QoQ basis from $359739.0 in Q1 2025.

Eupraxia Pharmaceuticals (EPRX) Non Operating Income (2025 - 2026) Analysis & Trends

Eupraxia Pharmaceuticals (EPRX) has 2 years of Non Operating Income data on file, last reported at $3.3 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -9.22 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 444,000.00
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 188.30 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - 5.75 Mn
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -8.59 Mn
10 Eupraxia Pharmaceuticals 329.50 Mn 329.50 Mn - 3.32 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 3.32 Mn
Mar 31, 2025 359,739.00